Naglazyme (galsulfase injection)

Indications for Prior Authorization

Naglazyme (galsulfase injection)
  • For diagnosis of Mucopolysaccharidosis (MPS VI)
    Indicated for patients with Mucopolysaccharidosis VI (MPS VI). Naglazyme has been shown to improve walking and stair-climbing capacity.

Criteria

Naglazyme

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)

  • Diagnosis of Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)
Naglazyme

Prior Authorization (Reauthorization)

Length of Approval: 24 Month(s)

  • Patient demonstrates positive clinical response to therapy
P & T Revisions

2024-06-05, 2023-10-03, 2023-06-06, 2022-06-01, 2021-08-02, 2021-05-10, 2020-05-14

  1. Naglazyme Prescribing Information. BioMarin Pharmaceuticals Inc. April 2020.

  • 2024-06-05: 2024 Annual Review. No criteria changes.
  • 2023-10-03: Program update to standard reauthorization language. No changes to clinical intent
  • 2023-06-06: Initial auth shortened to 12 months. Reauth criteria created with 24 month approval.
  • 2022-06-01: Annual Review, no criteria changes.
  • 2021-08-02: 2021 UM Annual Review.
  • 2021-05-10: 2021 UM Annual Review.
  • 2020-05-14: Annual Review - Updated References

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone